Bianca Orlando

Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

F. Vernieri, C. Altamura, P. Barbanti, 2024, Journal of neurology.

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

L. Borrello, A. Doretti, G. Egeo, 2024, Neurology and therapy.

Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study

P. Barbanti, G. Egeo, C. Aurilia, 2024, Journal of neurology.